Cliff Asness’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.55M Buy
422,087
+177,696
+73% +$592K ﹤0.01% 2775
2026
Q1
$750K Buy
+244,391
New +$944K ﹤0.01% 2916
2025
Q4
Sell
-14,910
Closed -$72.8K 3633
2025
Q3
$72.8K Buy
14,910
+1,010
+7% +$5.3K ﹤0.01% 3397
2025
Q2
$70.3K Sell
13,900
-154,291
-92% -$758K ﹤0.01% 3220
2025
Q1
$890K Buy
+168,191
New +$1.23M ﹤0.01% 2099
2024
Q2
Sell
-14,985
Closed -$149K 2667
2024
Q1
$149K Buy
+14,985
New +$167K ﹤0.01% 2300

Other funds holding RXRX

Cliff Asness's RXRX Position: Q2 2026 in Review

Cliff Asness increased its Recursion Pharmaceuticals (RXRX) stake by 73% in Q2 2026, buying an estimated $592K and bringing the position to 422,087 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2775.

Cliff Asness first reported a position in RXRX in Q1 2024 and has held it in 6 quarters since. 339 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Cliff Asness held 422,087 shares of Recursion Pharmaceuticals worth $1.55M as of Q2 2026.
  • Cliff Asness bought 177,696 Recursion Pharmaceuticals shares in Q2 2026, an estimated $592K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2775 holding.
  • Cliff Asness first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • 339 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.